Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01775137 · ClinicalTrials.gov registry record · Phase 4
Ext. Long-term Safety Study in CF Patients: Single Arm TIP
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 45
- Enrollment target
NCT01775137 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 45 participants.
The verdict
NCT01775137, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this extension study is to collect additional 48 weeks of safety data from patients taking TIP who have completed the core study CTBM100C2401. The purpose of collecting second year safety data through this study is to obtain long-term (2 years) safety data of TIP.
Interventions
- DRUG TBM100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2013-02 |
| Est. Completion | 2014-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01775137
The ClinicalTrials.gov registry entry for NCT01775137 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TBM100 is the first listed.
NCT01775137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01775137 about?
NCT01775137 is a clinical study titled "Ext. Long-term Safety Study in CF Patients: Single Arm TIP". The purpose of this extension study is to collect additional 48 weeks of safety data from patients taking TIP who have completed the core study CTBM100C2401. The purpose of collecting second year safety data through this study is to obtain long-term (2 years) safety data of TIP.
What is the current status of trial NCT01775137?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 45 participants. The study started on 2013-02. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01775137?
The interventions under investigation include: TBM100 (DRUG).
Who is sponsoring clinical trial NCT01775137?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.